All In Biotech

Drug Trial Radar · NCT00368030

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD

Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 545 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

545

Actual

Start

Jan 2004

Primary completion

Oct 2004

Study completion Oct 2004

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.

Conditions

  • Insomnia
  • Depressive Disorder, Major

Interventions

  • EszopicloneDrug

    Eszopiclone 3 mg QD

  • PlaceboOther

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean subjective wake time after sleep onset (WASO)Time frame: 1 week

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Peoria, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Fayetteville, Arkansas

  • Site not named

    Garden Grove, California

  • Site not named

    Irvine, California

  • Site not named

    Northridge, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    New Britian, Connecticut

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Overland Park, Kansas

  • Site not named

    Rockville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Braintree, Massachusetts

  • Site not named

    Brighton, Massachusetts

  • Site not named

    Brockton, Massachusetts

  • Site not named

    Cambridge, Massachusetts

  • Site not named

    Watertown, Massachusetts

  • Site not named

    Farmington Hills, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Clementon, New Jersey

  • Site not named

    Morestown, New Jersey

  • Site not named

    Lawerence, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Bismarck, North Dakota

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.